Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Temozolomide

Review the clinical trials studying temozolomide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-87 of 87

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients with Progressing Metastatic Neuroendocrine Carcinomas
Status: Approved
Location: Roswell Park Cancer Institute, Buffalo, New York
Neoadjuvant Chemoradiotherapy with or without Azeliragon for the Treatment of Newly Diagnosed Glioblastoma
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors that have Returned after Previous Treatment
Status: Temporarily Closed to Accrual
Location: 34 locations
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Genetically Engineered Cells (P140K MGMT Hematopoietic Stem Cells), O6-Benzylguanine, Temozolomide, and Carmustine for the Treatment of Resected Supratentorial Glioblastoma or Gliosarcoma
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Onivyde in Combination with Talazoparib or Temozolomide for the Treatment of Recurrent or Refractory Solid Tumors and Ewing Sarcoma
Status: Temporarily Closed to Accrual
Location: 6 locations
Pharmacologic Ascorbate and Ferumoxytol Combined with Temozolomide and Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma
Status: Temporarily Closed to Accrual
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Hyperpolarized Imaging in Diagnosing Patients with Glioma
Status: Active
Location: 2 locations
Hyperpolarized Carbon C 13 Pyruvate MRI for the Diagnosis of Patients with Primary Central Nervous System Lymphoma
Status: Active
Location: University of California San Francisco, San Francisco, California
Rapid Infusion of Dinutuximab with Chemotherapy for the Treatment of Relapsed, Refractory or Persistent High Risk Neuroblastoma or Ganglioneuroblastoma
Status: Active
Location: Children's Hospital Los Angeles, Los Angeles, California
Implantable Microdevice for the Delivery of Drugs and their Effect on Tumors in Patients with Sarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Evaluating Advanced MRI Methods for Adapting Radiation Therapy for Patients with Newly Diagnosed High Grade Glioma
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York